TriNetX will provide Regeneron secure, licensed access to de-identified health data from its global network of health system partners
Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
Recognition across subsidiaries and geographies highlights pharma major’s focus on inclusive culture, employee experience, and global workforce development
Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.
In his new role, Saran will spearhead the end-to-end launch framework for innovation-led portfolio
With more than two decades of experience, he brings deep expertise in sales, marketing, business transformation, and strategic leadership
Minister highlights scope for domestic manufacturing during his meeting with Dr Niti Pall, President-elect, International Diabetes Federation
Company leadership is framing the move as transformational.
Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy
Subscribe To Our Newsletter & Stay Updated
